3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Fallopian Tube Neoplasms
10
Ovarian Neoplasms
7
Endometrial Neoplasms
5
Breast Neoplasms
4
Prostatic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Osteosarcoma
2
Neuroendocrine Tumors
2
Neuroblastoma
2
Neoplasms
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Glioma
2
Ependymoma
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Recurrence
1
Interventions
Magnetic Resonance Spectroscopy
4
Specimen Handling
3
Nivolumab
3
ulixertinib
2
binimetinib
2
Ipilimumab
2
Immunoglobulin G
2
Disulfides
2
Cetuximab
2
CTLA-4 Antigen
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
temsirolimus
1
selpercatinib
1
sapanisertib
1
repotrectinib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
olaparib
×
30 days
×
Clear all
No trials found.